

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS, INC.,  
Petitioner,

v.

ANACOR PHARMACEUTICALS, INC.,  
Patent Owner.

---

Case IPR2018-01359  
Patent 9,566,289 B2

---

Before GRACE KARAFFA OBERMANN, TINA E. HULSE, and  
JACQUELINE T. HARLOW, *Administrative Patent Judges*.

HULSE, *Administrative Patent Judge*.

DECISION

Institution of *Inter Partes* Review and Grant of Motion for Joinder  
*35 U.S.C. §§ 314(a), 315(c); 37 C.F.R. § 42.122(b)*

## I. INTRODUCTION

Mylan Pharmaceuticals, Inc. (“Mylan”) filed a Petition requesting an *inter partes* review of claims 1–15 of U.S. Patent No. 9,566,289 B2 (Ex. 1001, “the ’289 patent”). Paper 2 (“Pet.”). Along with the Petition, Mylan filed a Motion for Joinder to join this proceeding with *FlatWing Pharmaceuticals, LLC v. Anacor Pharmaceuticals, Inc.*, IPR2018-00169. Paper 3 (“Motion” or “Mot.”). Mylan filed the Petition and Motion on July 6, 2018, within one month after we instituted trial in IPR2018-00169 on June 8, 2018. 37 C.F.R. § 42.122(b); *see FlatWing*, IPR2018-00169, Paper 9 (PTAB June 8, 2018). Anacor Pharmaceuticals, Inc. (“Patent Owner”) filed an Opposition to Mylan’s Motion for Joinder<sup>1</sup> (Paper 8) and Mylan filed a Reply (Paper 10). In a subsequent e-mail correspondence to the Board on September 27, 2018, the parties informed the Board that Patent Owner “no longer opposes Mylan’s motions for joinder.” Ex. 3001.

As explained further below, we institute trial on the same grounds as instituted in IPR2018-00169 and grant Mylan’s Motion for Joinder.

## II. DISCUSSION

In IPR2018-00169, FlatWing Pharmaceuticals, LLC (“FlatWing”) challenged claims 1–15 of the ’289 patent on the following grounds:

---

<sup>1</sup> Patent Owner also filed a motion to request acceptance of its PTAB E2E submission due to technical difficulties with filing its Opposition. Paper 9. Absent opposition from Mylan, we find good cause exists to grant that request for the reasons stated in Patent Owner’s motion. *Id.* Patent Owner’s motion is, therefore, *granted*.

References	Basis	Claims challenged
Austin <sup>2</sup> and Brehove <sup>3</sup>	§ 103	1 and 2
Austin, Brehove, and Samour <sup>4</sup>	§ 103	4–7, 10, and 11
Austin, Brehove, Samour, and the Excipients Handbook <sup>5</sup>	§ 103	3, 8, 9, and 12–15
Austin and Freeman <sup>6</sup>	§ 103	1 and 2
Austin, Freeman, and Samour	§ 103	4–7, 10, and 11
Austin, Freeman, Samour, and the Excipients Handbook	§ 103	3, 8, 9, and 12–15

After considering the Petition (Patent Owner did not file a Preliminary Response), we instituted trial in IPR2018-00169 on all six grounds.

IPR2018-00169, Paper 9, 5, 16.

Mylan’s Petition is substantively identical to FlatWing’s Petition, challenging the same claims based on the same art and the same grounds. *Compare* IPR2018-00169, Paper 1 *with* IPR2018-01359, Paper 2. For the same reasons stated in our Decision on Institution in IPR2018-00169, we institute trial in this proceeding on the same four grounds. *See* IPR2018-00169, Paper 9.

---

<sup>2</sup> Austin et al., WO 95/33754, published Dec. 14, 1995 (“Austin,” Ex. 1007).

<sup>3</sup> Brehove, US 2002/0165121 A1, published Nov. 7, 2002 (“Brehove,” Ex. 1008).

<sup>4</sup> Samour et al., US 6,224,887 B1, issued May 1, 2001 (“Samour,” Ex. 1010).

<sup>5</sup> *Handbook of Pharmaceutical Excipients* (Arthur H. Kibbe, ed., 3d ed. 2000) (“Excipients Handbook,” Ex. 1011)

<sup>6</sup> Freeman et al., WO 03/009689 A1, published Feb. 6, 2003 (“Freeman,” Ex. 1009).

Having determined that institution is appropriate, we now turn to Mylan's Motion for Joinder. Based on authority delegated to us by the Director, we have discretion to join an *inter partes* review to a previously instituted *inter partes* review. 35 U.S.C. § 315(c). Section 315(c) provides, in relevant part, that "[i]f the Director institutes an inter partes review, the Director, in his or her discretion, may join as a party to that inter partes review any person who properly files a petition under section 311." *Id.* When determining whether to grant a motion for joinder we consider factors such as timing and impact of joinder on the trial schedule, cost, discovery, and potential simplification of briefing. *Kyocera Corp. v. SoftView, LLC*, Case IPR2013-00004, slip op. at 4 (PTAB Apr. 24, 2013) (Paper 15).

Under the circumstances of this case, we determine that joinder is appropriate. As Mylan notes, the Petition in this proceeding is substantially identical to the Mylan Petition with no substantive differences. Mot. 1–2. Mylan relies on the same expert declarations submitted in IPR2018-00169. *Id.* Moreover, Mylan has agreed to assume a "silent understudy" role in the joined proceedings, as long as FlatWing remains a party to the proceeding. Reply 1–3. Mylan further contends that there will be no impact on the trial schedule of IPR2018-00169, and that joinder will promote the just, speedy, and inexpensive resolution of the proceedings without prejudice to the parties. Mot. 4–8.

In view of the foregoing, we find that joinder based upon the conditions stated in Mylan's Motion for Joinder (and its Reply) will have little or no impact on the timing, cost, or presentation of the trial on the instituted grounds. Moreover, discovery and briefing will be simplified if the proceedings are joined. Thus, Mylan's Motion for Joinder is granted.

### III. ORDER

In consideration of the foregoing, it is hereby:

ORDERED that pursuant to 35 U.S.C. § 314(a), an *inter partes* review of claims 1–15 of the '289 patent is instituted with respect to all grounds set forth in the Petition;

FURTHER ORDERED that Mylan's Motion for Joinder with IPR2018-00169 is granted;

FURTHER ORDERED that IPR2018-01359 is terminated and joined to IPR2018-00169, pursuant to 37 C.F.R. §§ 42.72 and 42.122, based on the conditions stated in Mylan's Motion for Joinder (Papers 3, 10), as discussed above;

FURTHER ORDERED that the Scheduling Order in place for IPR2018-00169 (Paper 10) shall govern the joined proceedings;

FURTHER ORDERED that all future filings in the joined proceeding are to be made only in IPR2018-00169;

FURTHER ORDERED that the case caption in IPR2018-00169 for all further submissions shall be changed to add Mylan as a named Petitioner with FlatWing, and to indicate by footnote the joinder of IPR2018-01359 to that proceeding, as indicated in the attached sample case caption; and

FURTHER ORDERED that a copy of this Decision shall be entered into the record of IPR2018-00169.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.